-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
-
-
-
-
-
-
RBC Capital Downgrades Sarepta Therapeutics (SRPT) to Sector Perform
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) option implied volatility into PDUFA
-
-
-
-
-
-
-
BofA on Sarepta's (SRPT) 9001: All signs point to approval, but we think 3-month extension could occur
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) Reports Positive FDA AdCom Vote for SRP-9001
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) PT Lowered to $170 at Needham & Company
-
-
-
-
-
-
-
Pre-Open Stock Movers 03/01: (CLNE) (DVAX) (LOW) Higher; (PANW) (ENPH) (SRPT) Lower (more...)
-
15,536 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

